Ministry of Health – MS

Brazilian Health Surveillance Agency - ANVISA

RESOLUTION OF COLLEGIATE BOARD – RDC # 166, OF JULY 24, 2017

(Published in Brazilian Official Gazette #141 on July 25, 2017)

It provides for the validation of analytical methods

and other provisions.

The Collegiate Board of the Brazilian Health Surveillance Agency, in the use of the
attribution conferred by art. 15, III and IV allied to art. 7, III and IV of Law No. 9,782 of
January 26, 1999, and to art. 53, V, Paragraph 1 and Paragraph3 of the Internal Regulations
approved in accordance with Annex I of the Resolution of the Collegiate Board of Directors -
RDC No. 61 of February 3rd, 2016, resolves to adopt the following Resolution of the Collegiate
Board of Directors, as resolved at a meeting held On July 11th, 2017, and I, the Chief Executive
Officer, hereby determine its publication.

CHAPTER I
INITIAL PROVISIONS

Section I

Objective

Art. 1 This Resolution establishes criteria for the validation of analytical methods.

Sole paragraph. Failure to comply with any of the criteria set forth in this Resolution must be
technically justified and subject to analysis by ANVISA.

Section II

Scope

Art. 2 This Resolution applies to analytical methods used in pharmaceutical ingredients,

drugs and biological products at all stages of production.

Paragraph 1 - Validation parameters and their respective acceptance criteria shall be

defined according to the characteristics of the analyte and the nature of the method.

Paragraph 2 - Analytical methods applied to the products under investigation used in

clinical trials shall have their suitability demonstrated in accordance with this Resolution, as
applicable for each phase of clinical development.

I - The use of an alternative approach must be technically justified based on recognized

scientific references.

Paragraph 3 - The use of alternative approaches for the validation of analytical methods
applied to biological products, such as biological and immunological tests, shall be permitted.

This text does not replace the text(s) published in the Brazilian Official Gazette
 Ministry of Health – MS
Brazilian Health Surveillance Agency - ANVISA

Paragraph 4 - Microbiological methods for which a technical justification for the chosen
approach based on the Brazilian Pharmacopoeia or other official compendia recognized by
ANVISA are excluded from this Resolution.

Section III

Definitions

Art. 3 For the purposes of this Resolution, the following definitions are adopted:

I.- Sample: representative quantity of pharmaceutical ingredient, intermediate product or

finished product, duly identified, within the established period of validity;

II.- Analyte: substance or set of substances of interest to be identified or quantified;

III.- Characterization of chemical substance: this is the set of tests which unequivocally
guarantees the authenticity and quality of the substance as regards its identity, purity, content
and strength and shall include data obtained from techniques applicable to the characterization
of each substance, for example, thermogravimetry, melting point, differential scanning
calorimetry, infrared spectroscopy, mass spectrometry, nuclear magnetic resonance, elemental
(carbon / hydrogen / nitrogen) analysis, X-ray diffraction, optical rotation, chromatographic
assays, among others;

IV.- Analytical run: set of measurements performed on a group of samples within a

predetermined time point under the same repeatability conditions, such as method, analyst,
instrumentation, location and conditions of use;

V.- Matrix effect: effect of matrix components on analytical response;

VI.- Test: a technical operation consisting of the determination of one or more

characteristics of a given ingredient or product according to a specified method;

VII.- Limit test: tests to verify that the amount of analyte is above or below a pre-
established level, without quantifying it accurately;

VIII.- Response factor: ratio between analytical signal and analyte concentration;

IX.- Relative response factor: ratio between two response factors, which is used as
correction in the calculation of the concentration of a substance when it is measured by means
of the analytical response of another;

X.- Quality management: this is what determines the implementation of the "Quality
Policy", that is, the overall intentions and guidelines regarding quality, formally expressed and
authorized by the superior management of the company;

This text does not replace the text(s) published in the Brazilian Official Gazette
 Ministry of Health – MS
Brazilian Health Surveillance Agency - ANVISA

XI.- Impurities: any component present in the pharmaceutical ingredient or the finished
product other than the active pharmaceutical ingredient or the excipient;

XII.- Pharmaceutical ingredient: any substance being part of the formulation in a

pharmaceutical form;

XIII.- Active pharmaceutical ingredient (API): a pharmaceutical ingredient that, when

administered to a patient, acts as an active component, and can exert pharmacological activity or
direct effect in the diagnosis, cure, treatment or prevention of a disease or even affect the
structure and functioning of the human organism;

XIV.- Complex matrix: one containing an undefined number of unmonitored substances,

which cannot be obtained without the presence of the analyte;

XV.- Matrix: composition that mimics the sample without the presence of the analyte;

XVI.- Investigational product: experimental drug, placebo, active comparator or any other
product to be used in the clinical trial;

XVII.- Chromatographic purity: absence of interference in the chromatographic signal of

the analyte;

XVIII.- Peak purity: spectral homogeneity of a chromatographic peak, indicative of its

chromatographic purity, and the criteria for concluding whether there is spectral homogeneity
and the parameters adopted for the purity calculation are defined as previously established for
the software used or by means of scientifically based evaluation technique;

XIX.- Validation report: document in which the validation procedures, records, results and
evaluation are consolidated and summarized;

XX.- Revalidation of analytical method: partial or complete re-validation of an analytical

method to ensure that it continues to comply with established requirements;

XXI.- Chemical Reference Substance (CRS): substance or mixture of high purity chemical
or biological substances, which has been carefully characterized to ensure its identity, quality,
content and potency, including a characterized chemical reference substance and a
pharmacopoeial chemical reference substance;

XXII.- Characterized Chemical Reference Substance (CCRS): Substance or mixture of

chemical or biological substances in which identity, quality, purity, content and strength have
been ensured by a characterization process;

XXIII.- Pharmacopoeial Chemical Reference Substance (PCRS): Substance or mixture of

chemical or biological substances established and distributed by official compendia recognized
by ANVISA;

This text does not replace the text(s) published in the Brazilian Official Gazette
 Ministry of Health – MS
Brazilian Health Surveillance Agency - ANVISA

XXIV.- Working Chemical Reference Substance (WCRS): Substance or mixture of

chemical or biological substances used in the laboratory routine, standardized from a
pharmacopoeial reference chemical or, in the absence thereof, from a characterized chemical
reference substance, traceable to the CRS used for its standardization;

XXV.- Method transfer: a documented process that qualifies a laboratory (receiving unit)
for the use of an analytical method from another laboratory (transfer unit), ensuring that the
receiving unit is knowledgeable and capable of performing the analytical method according to
intended purpose;

XXVI.- Analytical validation: is the systematic evaluation of a method by means of

experimental tests in order to confirm and provide objective evidence that the specific
requirements for its intended use are met;

XXVII.- Partial validation: demonstration, through some validation parameters, that the
previously validated analytical method has the necessary characteristics to obtain results with
the required quality, under the conditions in which it is practiced; and

XXVIII.- System suitability: Procedure to be carried out prior to an analytical run to

demonstrate that the system is fit for the intended use, and the parameters of this procedure
must be defined during the development and validation of the method.

CHAPTER II

GENERAL PROVISIONS

Art. 4 Validation shall demonstrate that the analytical method produces reliable results and
is appropriate to the intended purpose, in a documented manner and through objective criteria.

Art. 5 The use of analytical method not described in an official compendium recognized by
ANVISA requires the conduction of an analytical validation, according to the parameters
established in this resolution, taking into account the technical-operational conditions.

Art. 6 The typical parameters to be considered for validation depend on the test to be
carried out and are set out in Table 1 of Annex I.

Art. 7 Compendial analytical methods must have their demonstrated suitability for the
intended use, under the operational conditions of the laboratory, by means of the presentation of
a partial validation study.

This text does not replace the text(s) published in the Brazilian Official Gazette
 Ministry of Health – MS
Brazilian Health Surveillance Agency - ANVISA

Sole paragraph. The provisions of the caput exclude basic general compendial methods
such as pH measurement, drying loss, sulfated ash, moisture, disintegration, among others, and
the analytical methods described in individual compendial monographs of non-active
pharmaceutical ingredients.

Art. 8 Partial validationvalidations shall evaluate, at least, the parameters of precision,

accuracy and selectivity.

Paragraph 1 - In case of analytical methods for quantification of impurities, partial

validation shall include the quantification limit.

Paragraph 2 - In case of a limit test, instead of the parameters of the caput, the selectivity
and detection limit parameters must be evaluated.

Art. 9 In case of transfer of method between laboratories, this will be considered as

validated, provided that a partial validation study is carried out in the premises of the receiving
laboratory.

Paragraph 1 - Transfer of method between laboratories with the same quality management
system can be carried out by means of a partial validation study, according to art. 8, or by
reproducibility assessment.

Paragraph 2 - Another approach may be accepted, based on justification and presentation

of protocol and transfer report, based on risk analysis and considering previous experience,
knowledge of the receiving unit, complexity of product and method and specifications, as well
as other applicable relevant aspects.

Paragraph 3 - If the transfer also uses comparative tests, the similarity in the results should
be proven by means of statistical tool.

Paragraph 4 - The method transfer documentation shall be presented containing the copy of
the validation report of the transferred method as proof that it was originally validated in
accordance with specific standards and regulations approved/endorsed by ANVISA.

Paragraph 5 - In the case of transfer of methods already approved by ANVISA a copy of

the approved validation report or an indication of the file number of the petition in which the
final version of that report has been filed.

Art. 10. A revalidation of analytical method may consider the following circumstances:

I.- changes in the synthesis or obtainment of API;

II.- changes in product composition;

III.- changes in analytical method; and

This text does not replace the text(s) published in the Brazilian Official Gazette
 Ministry of Health – MS
Brazilian Health Surveillance Agency - ANVISA

IV.- other changes that could significantly impact the validated method.

Sole paragraph. The validation parameters to be evaluated depend on the nature of the
changes made.

Art. 11 System verification shall be carried out at each analytical run.

Art. 12 The validation and partial validation documents submitted shall describe the
procedures, analytical parameters, acceptance criteria and results, with sufficient detail to enable
their reproduction and, where applicable, their statistical evaluation.

Art. 13 The validation report to be filed, according to registration and post-registration

resolutions, shall contain the data and calculations obtained during the conduction of the
analytical validation, as well as the statistical approach used for data evaluation.

Paragraph 1 - The raw data related to the selectivity parameter should be part of the report
mentioned in the caput.

Paragraph 2 - The raw data related to other parameters must be available at the company
for evaluation at ANVISA’s request.

CHAPTER III

CHEMICAL REFERENCE SUBSTANCES

Art. 14 In the validation of analytical methods Pharmacopoeial Chemical Reference

Substance (PCRS) should be preferably used, officially designated by the Brazilian
Pharmacopoeia, or by other compendia officially recognized by ANVISA.

Paragraph 1. The use of Characterized Chemical Reference Substance (CCRS) will be

admitted by submitting a conclusive characterization report for the batch under study, including
the technical reasons for choosing the tests used and the relevant raw data.

Paragraph 2 - ANVISA and members of the Brazilian Health Surveillance System may
request samples from the CRS for the purpose of evaluating the characterization process in the
hypotheses of the previous paragraph and, when it is necessary to carry out a fiscal analysis, a
sample of CRS should be provided for the purposes of realization of the necessary tests.

Art. 15 The characterization report, depending on the analyte, shall contain the data
obtained from techniques applicable to the characterization of each chemical such as
thermogravimetry, melting point, differential scanning calorimetry, infrared spectroscopy, mass
spectrometry, nuclear magnetic resonance, elemental analysis (carbon/hydrogen/nitrogen), X-
ray diffraction, optical rotation, chromatographic methods, among others.

This text does not replace the text(s) published in the Brazilian Official Gazette
 Ministry of Health – MS
Brazilian Health Surveillance Agency - ANVISA

Paragraph 1 - In addition to the characterization data, the following information should be

included in the report:

I.- number and shelf-life of the batch of the substance used in the characterization;

II.- Brazilian non-proprietary name or international non-proprietary name;

III.- CAS number;

IV.- chemical name;

V.- synonymy;

VI.- molecular and structural formula;

VII.- molecular weight;

VIII.- physical form;

IX.- physicochemical properties;

X.- impurity profile;

XI.- handling and conservation care, and

XII.- Analytical report proving the identity, content and validity of CRS.

Paragraph 2 - For biological products, the characterization of the reference

material/standard shall be carried out using appropriate state of the art methods.

Art. 16 For medical gases, analytical instrument verification and analytical determinations
shall be conducted using traceable reference materials distributed by metrology institutes or by
bodies recognized as producers of certified reference materials.

Sole paragraph. In the absence of reference materials, internal standards produced

according to guides and bibliographic records may be used.

Article 17 For biological products, the terms material/standard substitutes the term
chemical substance in the definitions of CRS, PCRS, CCRS and WCRS.

Art. 18 The use of WCRS for the purpose of analytical method validation is not allowed.

This text does not replace the text(s) published in the Brazilian Official Gazette
 Ministry of Health – MS
Brazilian Health Surveillance Agency - ANVISA

CHAPTER IV

ANALYTICAL VALIDATION PARAMETERS

Section I

Selectivity

Art. 19 The selectivity of the analytical method should be demonstrated by its ability to
identify or quantify the analyte of interest unambiguously in the presence of components that
may be present in the sample such as impurities, diluents and matrix components.

Sole paragraph. In the case of chromatographic methods, the chromatographic purity of the
analyte signal must be demonstrated, except for biological products.

Art. 20 In identification methods, the ability to obtain a positive result for the sample
containing the analyte and a negative result for other substances in the sample.

Paragraph 1 - CRS shall be used in comparison with the response obtained for the analyte
under Chapter III.

Paragraph 2 - In order to demonstrate the selectivity of the identification methods, the tests
shall be applied to substances structurally similar to the analyte, with the acceptance criterion
being negative.

Paragraph 3 - For active pharmaceutical ingredients derived from plants and medicinal
products containing them, the ability of the method of distinguishing material of interest from
other similar plant species, particularly those which may be present as adulterants or
substituents.

Paragraph 4 - To achieve the required level of selectivity, a combination of two or more

analytical methods of identification may be required.

Art. 21 For quantitative methods and limiting tests, the selectivity shall be demonstrated by
verifying that the analytical response is exclusively due to the analyte, without interference from
the diluent, matrix, impurities or degradation products.

Paragraph 1 - To demonstrate the absence of interference degradation products, it is

necessary to expose the sample to degradation conditions in a wide pH range, oxidation, heat
and light.

Paragraph 2 - The following cases shall be exempted from the demonstration described in
Paragraph 1:

This text does not replace the text(s) published in the Brazilian Official Gazette
 Ministry of Health – MS
Brazilian Health Surveillance Agency - ANVISA

I.- products for which it has already been shown to comply with the resolution that
establishes parameters for the notification, identification and qualification of degradation
products in drugs.

II.- performance methods;

III.- non-chromatographic methods.

Paragraph 3 - The use of a method with technical limitation for selectivity, under the caput,
is only accepted by technical justification and joint application of another complementary
method.

Art. 22 For medicinal gases, selectivity should be demonstrated by comparing the result of
reading the sample with the reading response of CRS under Chapter III.

Sole paragraph. The maximum amount of possible interference should be justified.

Section II

Linearity

Art. 23 The linearity of a method must be demonstrated by its ability to obtain analytical
responses directly proportional to the concentration of an analyte in a sample.

Art. 24 A linear relationship must be evaluated throughout the established range for the
method.

Art. 25 For the establishment of linearity, at least 5 (five) different concentrations of CRS
must be used for solutions prepared in at least triplicate.

Sole paragraph. The solutions used for linearity evaluation must be prepared
independently, and diluted solutions of the same CRS stock solution may be used.

Art. 26 All calculations for the assessment of linearity shall be performed from actual
concentration data and individual analytical responses.

Art. 27 For the assessment of linearity, the following data shall be presented:

I.- graphical representation of the responses as a function of analyte concentration;

II.- graph of dispersion of the residues, accompanied by its statistical evaluation;

III.- equation of the regression line of y in x, estimated by least squares method;

This text does not replace the text(s) published in the Brazilian Official Gazette
 Ministry of Health – MS
Brazilian Health Surveillance Agency - ANVISA

IV.- evaluation of the linear association between the variables by means of the coefficients
of correlation (r) and determination (r²);

V.- significance evaluation of the angular coefficient.

Paragraph 1 - Homoscedasticity of the data shall be investigated for use of the appropriate
model.

Paragraph 2 - Statistical tests should be used a significance level of 5% (five percent).

Paragraph 3 - The correlation coefficient should be above 0.990.

Paragraph 4 - The angular coefficient shall be significantly different from zero.

Section III

Matrix Effect

Art. 28 The provisions of this section apply to complex matrices.

Art. 29 The matrix effect must be determined by comparing the angular coefficients of the
calibration curves constructed with the CRS of the analyte in solvent and with the sample
fortified with the CRS of the analyte.
Sole paragraph. The curves shall be established in the same way as in the linearity for the
same concentration levels, using at least 5 (five) different concentrations in at least triplicate.

Art. 30 The parallelism of the lines is indicative of interference absence of the matrix
constituents and its demonstration must be carried out by means of adequate statistical
evaluation.

Sole paragraph. The level of significance of 5% (five percent) should be adopted in the
hypothesis test.

Section IV

Working range

Art. 31 The working range must be established from the linearity studies, together with the
results of precision and accuracy, being dependent on the intended application.

Art. 32 The following working ranges should be considered:

I.- for content: from 80% (eighty percent) to 120% (one hundred and twenty percent);

This text does not replace the text(s) published in the Brazilian Official Gazette
 Ministry of Health – MS
Brazilian Health Surveillance Agency - ANVISA

II.- for uniformity of content: from 70% (seventy percent) to 130% (center and thirty
percent);

III.- for dissolution test: from -20% (minus twenty percent) of the lowest expected
concentration to + 20% (plus twenty percent) of the highest concentration expected from the
dissolution profile; and

IV.- for determination of impurities: from the limit of quantification up to 120% (one
hundred and twenty percent) of the concentration at the limit of the specification of each
individual impurity;

V.- for simultaneous determination of content and impurities by the area normalization
procedure: from the limit of quantification (LQ) up to 120% (one hundred and twenty percent)
of the expected concentration of the active substance.

Paragraph 1 - Larger working ranges than those defined in the caput may be used if
technically justified.

Paragraph 2 - For medicinal gases, alternate working ranges shall be accepted provided that
the approach for the choice of range is justified.

Section V

Precision

Art. 33 The precision shall evaluate the proximity between the results obtained by means of
tests with samples prepared as described in the analytical method to be validated.

Art. 34 Precision shall be expressed by means of repeatability, intermediate precision or

reproducibility.

Art. 35 Precision must be demonstrated by scattering the results, calculating the relative
standard deviation (RSD) of the series of measurements according to the formula "RSD = (SD /
DAC) X100", where SD is the standard deviation and DAC, determined average concentration.

Art. 36 Samples for precision evaluation shall be prepared independently from the
beginning of the procedure described in method.

Sole paragraph. In the case of solid and semi-solid samples, diluted solutions of the same
stock solution are not acceptable.

Art. 37 Where the precision assessment involves contamination of the matrix with a very
low-quantity substance which makes direct weighing impossible, a concentrated solution of the
substance may be used following the procedure described in the analytical method for extraction
and dilution of the sample.

This text does not replace the text(s) published in the Brazilian Official Gazette
 Ministry of Health – MS
Brazilian Health Surveillance Agency - ANVISA

Paragraph 1 - In the case of known impurities absent or present in concentrations below the
specification limit in the sample, the sample shall be fortified with known concentrations of the
impurities standard.

Paragraph 2 - In the case of unknown impurities, the sample shall be evaluated using the
response of the active added to the matrix in the concentration corresponding to the limit of the
specification established for the impurity, provided that the same response factor for impurity
and for the active.

Art. 38 The determination of repeatability shall comply with the following criteria:

I - evaluate the samples under the same operating conditions, same analyst and same
instrumentation, in a single analytical run.

II - using at least 9 (nine) determinations, taking into account the linear interval of the
analytical method, i.e. 3 (three) concentrations: low, medium and high, with 3 replicates at each
level or 6 (six) replicates at 100% (one hundred percent) of the test concentration individually
prepared.

Art. 39 The acceptance criteria shall be defined and justified in accordance with the
following aspects:

I - purpose of the method;

II - intrinsic variability of the method;

III – work concentration; and

IV – sample analyte concentration in the sample.

Art. 40 The determination of intermediate precision shall meet the following criteria:

I.- express the proximity between the results obtained from the analysis of the same
sample, in the same laboratory, on at least two different days, performed by different operators;
and

II. - contemplating the same concentrations and the same number of determinations
described in the repeatability evaluation.

Art. 41 Reproducibility should be obtained by means of the proximity of the results

obtained in different laboratories.

Paragraph 1 - Reproducibility is applicable in collaborative studies or in the standardization

of analytical methods for inclusion in official compendia, by appropriate statistical tests.

Paragraph 2 - The acceptance criteria for the relative standard deviation must be justified as
recommended in art. 39.

This text does not replace the text(s) published in the Brazilian Official Gazette
 Ministry of Health – MS
Brazilian Health Surveillance Agency - ANVISA

Section VI

Accuracy

Art. 42 The accuracy of an analytical method must be obtained by the degree of agreement
between the individual results of the method under study in relation to a value accepted as true.

Art. 43 The accuracy must be verified from at least 9 (nine) determinations, considering the
linear interval of the analytical method, i.e. 3 (three) concentrations: low, medium and high,
with 3 (three) replicates at each level.

Art. 44 Samples for evaluation of accuracy should be prepared independently and diluted
solutions of the same CRS stock solution may be used.

Art. 45 For the determination of accuracy, the most appropriate approach must be used,
according to the analytical method under study:

I.- for API:

a) apply the proposed method using a substance with known purity (CRS);

b) compare the results with those resulting from a second validated method, whose
accuracy has been established; or

c) in the case of complex matrix analyte, perform analysis by the CRS addition method in
which known quantities of CRS are added to the sample.

II.- for finished product:

a) apply the proposed method in the analysis of a sample, in which known quantity of CRS
was added to the matrix;

b) in the unavailability of samples of all components of the drug, analysis may be carried
out by the CRS addition method in which known amounts of CRS are added to the solution of
the finished product; or

c) compare the results obtained with those resulting from a second validated method.

III.- for impurities:

a) apply the standard addition method in which known amounts of impurities or

degradation products are added to the sample;

b) in the unavailability of samples of certain impurities or degradation products, a

comparison of the results obtained with a second validated method and the use of the response
factor relative to the API;

This text does not replace the text(s) published in the Brazilian Official Gazette
 Ministry of Health – MS
Brazilian Health Surveillance Agency - ANVISA

c) for unknown impurities, accuracy shall be assessed by comparing the API’s CRS or
known impurity response, according to the proposed method, in a concentration range that
contemplates the working range of the method, provided that the same response factor is
considered.

Sole paragraph. In all cases, the method of calculating analyte concentrations shall be the
same as that described in the concerned analytical method.

Art. 46 The accuracy shall be expressed by the percentage recovery ratio of the known
analyte added to the sample or by the ratio between the experimentally determined mean
concentration and the corresponding theoretical concentration given by formula 1 of Annex II.

Sole paragraph. When accuracy is determined from a previously validated method, the
concentration of analyte determined by it should be considered, replacing the term "theoretical
concentration".

Art. 47 The standard relative deviation (SRD) should be calculated for each concentration.

Art. 48 The acceptance criteria for percentages of recovery and relative standard deviation
obtained must be justified according to the criteria recommended in art. 39.

Section VII

Detection Limit

Art. 49 Detection limit shall be demonstrated by obtaining the smallest amount of analyte
presented in a sample that can be detected but not necessarily quantified under the established
experimental conditions.

Art. 50 The determination of the detection limit can be carried out by means of a visual
method, the signal-to-noise ratio, based on the determination of the blank or parameters of the
calibration curve, considering the particularities of the analytical method used.

Art. 51 For visual methods, the detection limit is determined by the lower concentration for
which the visual effect expected.

Art. 52 For instrumental methods, the limit of detection can be determined by the signal-to-
noise ratio.

Paragraph 1 - The method used to determine the signal-to-noise ratio shall be described and
justified.

Paragraph 2 - The signal-to-noise ratio must be greater than or equal to 2:1.

This text does not replace the text(s) published in the Brazilian Official Gazette
 Ministry of Health – MS
Brazilian Health Surveillance Agency - ANVISA

Art. 53 For the determination based on analytical curve parameters, the detection limit may
be calculated by formula 2 of Annex II.

Art. 54 In cases where an estimated value for the detection limit is obtained by calculation
or extrapolation, this estimate must be confirmed according to art. 52.

Section VIII

Quantification Limit

Art. 55 The quantification limit is the smallest amount of analyte in a sample that can be
determined with acceptable precision and accuracy under established experimental conditions.

Art. 56 The quantification limit shall be consistent with the impurity specification limit.

Sole paragraph. For products suitable for the resolution setting out parameters for the
notification, identification and qualification of degradation products in medicinal products, the
quantification limit must be less than or equal to the notification limit.

Art. 57 For the determination of this parameter the same procedure described in art. 53, and
the signal-to-noise ratio must be at least 10:1.

Art. 58 For the determination based on analytical curve parameters, the quantification limit
may be calculated by formula 3 of Annex II.

Art. 59 In cases where an estimated value for the quantification limit is obtained by
calculation or extrapolation, this estimate must be confirmed according to art. 57.

Art. 60 Precision and accuracy at the concentrations corresponding to the quantification

limit must be tested.

Section IX

Robustness

Art. 61 Robustness is a parameter typically carried out in the development of the analytical
method that indicates its ability to withstand small and deliberate variations of analytical
conditions.

Sole paragraph. If the method is susceptible to variations in analytical conditions, these

should be controlled by precautions described in the method.

This text does not replace the text(s) published in the Brazilian Official Gazette
 Ministry of Health – MS
Brazilian Health Surveillance Agency - ANVISA

Art. 62 In the case of quantitative methods, the impact of proposed variations on the results
obtained shall be evaluated using the same criteria used for accuracy.

Art. 63 In the case of qualitative methods, it should be checked whether the proposed
variations interfere in the analytical response.

Art. 64 Compliance to the system verification characteristics shall be demonstrated. Art. 65

The assessment of the parameters described in Table 1 of Annex III shall be included in the
validation report.

Paragraph 1 - Parameters that are considered relevant to the result, according to the
characteristics of the method, should be additionally evaluated.

Paragraph 2 - The absence of the evaluation of any of the variations shall be justified.

CHAPTER V

TRANSITIONAL PROVISIONS

Art. 66 Analytical method validations will be accepted in compliance with Resolution RE

No. 899/2003, since it has been finalized prior to the validity of this resolution and the petitions
containing them have been filed within 550 (five hundred and fifty) calendar days after the
validity of this resolution.

Paragraph 1 - In case of the need to execute and re-present one or more validation
parameters, as long as a new validation is not required, the company may follow Resolution RE
No. 899, dated May 29th, 2003.

Paragraph 2 - In case of need to execute and submit a new validation, the company must
follow this resolution.

Paragraph 3 - After the deadline established in the caput for investigational products whose
validation of the analytical method used in clinical development has been initiated before the
validity of this regulation, the analytical validations carried out according to Resolution RE No.
899 dated May 29th, 2003 will be accepted at the time of registration.

CHAPTER VI

FINAL PROVISIONS

Art. 67 Additional documentation and tests may be requested at any time by ANVISA.

This text does not replace the text(s) published in the Brazilian Official Gazette
 Ministry of Health – MS
Brazilian Health Surveillance Agency - ANVISA

Art. 68 All relevant data obtained during the conduction of the analytical validation, as
well as the formulas used for calculation, must be filed together with the petition of interest for
the evaluation of ANVISA.

Art. 69 Failure to comply with the provisions contained in this resolution constitutes a
sanitary infraction, pursuant to Law No. 6.437, dated August 20th, 1977, without prejudice to the
applicable civil and criminal liability.

Art. 70 Resolution RE No. 899, dated May 29th, 2003, Subsection XXXI of art. 1, sole
paragraph of art. 11 and Annex I of Resolution RDC No. 31 dated August 11th, 2010 are
revoked.

Art. 71 This Resolution shall enter into force within a period of 180 (one hundred and
eighty) calendar days from the date of its publication.

JARBAS BARBOSA DA SILVA JR.

This text does not replace the text(s) published in the Brazilian Official Gazette
 Ministry of Health – MS
Brazilian Health Surveillance Agency - ANVISA

This text does not replace the text(s) published in the Brazilian Official Gazette
 Ministry of Health – MS
Brazilian Health Surveillance Agency - ANVISA

ANNEX I

Table 1. Parameters to be considered in analytical validation.

Impurity
Test Assay
- dissolution (quantification)
Evaluated Parameter Identification
- content uniformity
- strength
Quantitative Limit Test

Accuracy No Yes No Yes

Repeatability precision No Yes No Yes
Intermediate Precision No Yes (1) No Yes (1)
Selectivity (2) Yes Yes Yes Yes
Detection Limit No No (3) Yes No
Quantification Limit No Yes No No (3)
Linearity No Yes No Yes
Interval No Yes No Yes

This text does not replace the text(s) published in the Brazilian Official Gazette
 Ministry of Health – MS
Brazilian Health Surveillance Agency - ANVISA

(1) In cases where reproducibility has been conducted, it is not necessary to conduct intermediate
precision.

(2) In the case of identification tests, it may be necessary to combine two or more analytical
procedures to achieve the required level of discrimination.

(3) May be necessary in some cases.

ANNEX II

Formula 1. Accuracy calculation.

Experimental mean concentration

Recovery = __________________________________________________ x 100
Theoretical concentration

or

CA (added sample) - CA (sample)

Recovery = _________________________________________________ x 100
CTA

Where: CA is the experimental concentration of the analyte and CTA is the theoretical
concentration of the added analyte

LD = 3.3. σ
IC

Where: IC is the slope of the calibration curve, σ is the standard deviation and can be
obtained in 3 ways:

I - from the standard deviation of the Y-axis intercept of at least 3 calibration curves
constructed containing analyte concentrations close to the assumed detection limit;

This text does not replace the text(s) published in the Brazilian Official Gazette
 Ministry of Health – MS
Brazilian Health Surveillance Agency - ANVISA

II - from the residual standard deviation of the regression line;

III - from the estimation of noise coming from the analysis of an appropriate number of
blank samples.

Formula 3. Calculation of quantification limit.

LQ = 10. σ
IC

Where: IC is the slope of the calibration curve,curve; σ is the standard deviation and can be
obtained in 3 ways:

I - from the standard deviation of the Y-axis intercept of at least 3 calibration curves
constructed containing analyte concentrations close to the assumed detection limit;

II - from the residual standard deviation of the regression line;

III - from the estimation of noise coming from the analysis of an appropriate number of
blank samples.

ANNEX III

Table 1. Conditions for the evaluation of the method robustness

Stability of analytical solutions

Sample preparation Extraction time

Filter compatibility

pH variation of the solution

Spectrophotometry
Different solvent batches or manufacturers

pH variation of the mobile phase

Different column batches or manufacturers

Liquid Chromatography
Temperature

Mobile phase flow

This text does not replace the text(s) published in the Brazilian Official Gazette
 Ministry of Health – MS
Brazilian Health Surveillance Agency - ANVISA

Different column batches or manufacturers

Gas Chromatography Temperature

Carrier gas velocity

The variations to be tested should be evaluated critically and

Other analytical techniques
their results should be presented

This text does not replace the text(s) published in the Brazilian Official Gazette